Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Current Medicinal Chemistry|July 16, 2011
How would composite traditional Chinese medicine protect the brain--an example of the composite formula "Pien Tze Huang"L Zhang, W P Lam, L Lü, et al.
Diabetes, Obesity & Metabolism|May 16, 2018
Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open-label clinical trialPriscilla A Hollander, Wendy L Carofano, Raymond L H Lam, et al.
Diabetes, Obesity & Metabolism|November 6, 2018
Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I StudyRonan Roussel, Santiago Duran-García, Yilong Zhang, et al.
Journal of Neurology|August 28, 2024
Does repetitive transcranial magnetic stimulation have a beneficial effect on improving unilateral spatial neglect caused by stroke? A meta-analysisRuixuan Lin, Jack Jiaqi Zhang, Lingling Zhong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2015
Extent and Location of Tumor-Infiltrating Lymphocytes in Microsatellite-Stable Colon Cancer Predict Outcome to Adjuvant Active Specific ImmunotherapyAnnelies W Turksma, Veerle M H Coupé, Marc C Shamier, et al.
Pediatric Diabetes|November 15, 2021
Efficacy and safety of the addition of sitagliptin to treatment of youth with type 2 diabetes and inadequate glycemic control on metformin without or with insulinMuhammad Yazid Jalaludin, Asma Deeb, Philip Zeitler, et al.
Pediatric Diabetes|November 15, 2021
A randomized clinical trial of the efficacy and safety of sitagliptin as initial oral therapy in youth with type 2 diabetesR Ravi Shankar, Philip Zeitler, Asma Deeb, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 2021
Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINEE P Mamounas, M Untch, M S Mano, et al.
Pageof 3